While more research is needed to understand the role of DPP-4 in GDM, the existing literature suggests that DPP-4i (i.e., gliptin) therapy could help mitigate the capacity of GDM to program the fetus for future obesity and metabolic disease [16]. This evidence concerns the gene DPP4 and Obesity.